Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative age effect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    642 result(s) found for: Relative age effect. Displaying page 2 of 33.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000657-39 Sponsor Protocol Number: 0217/DEV Start Date*: 2017-08-15
    Sponsor Name:Develco Pharma Schweiz AG
    Full Title: Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid i...
    Medical condition: Opioid induced constipation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10071128 Opioid induced constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) ES (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004311-31 Sponsor Protocol Number: 0177/DEV Start Date*: 2013-03-20
    Sponsor Name:Develco Pharma Schweiz AG
    Full Title: Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets a...
    Medical condition: Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric re...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10071128 Opioid induced constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SK (Completed) ES (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001031-31 Sponsor Protocol Number: CRTH258BDE01 Start Date*: 2019-10-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A comperative BouBle Masked, Two-Arm, Randomized, MUlticenter, Phase IIb Study analyZing the Efficacy and Safety of BroluciZumab versus Aflibercept in Paients with Visual ImpaiRment due to Diabetic...
    Medical condition: diabetic macular edema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000716-28 Sponsor Protocol Number: CRTH258A2303 Start Date*: 2019-09-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in pa...
    Medical condition: neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000499-83 Sponsor Protocol Number: 1386.4 Start Date*: 2017-05-04
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orall...
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) IE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003218-14 Sponsor Protocol Number: 0176/DEV Start Date*: 2013-01-22
    Sponsor Name:Develco Pharma Schweiz AG
    Full Title: Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets a...
    Medical condition: Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric re...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10071128 Opioid induced constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) SK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002164-16 Sponsor Protocol Number: CPH-301-201030 Start Date*: 2016-04-11
    Sponsor Name:CROMA-PHARMA GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001521-31 Sponsor Protocol Number: D5982C00008 Start Date*: 2021-04-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Me...
    Medical condition: Severe and inadequately controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001981-13 Sponsor Protocol Number: INCB54707204 Start Date*: 2021-03-02
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005399-32 Sponsor Protocol Number: DPP-IVEPC Start Date*: 2013-01-22
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Randomized, open label, two parallel arms, intervention trial comparing the effect of DPP-IV inhibitor Vildagliptin vs. Glibenclamide on circulating EPCs.
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10012614 Diabetes mellitus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002895-29 Sponsor Protocol Number: BAY94-8862/18290 Start Date*: 2016-10-28
    Sponsor Name:Bayer AG
    Full Title: Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of single oral doses of finerenone 1.25 mg and 5 x 0.25 mg oro-dispersible tablet (pediatric formulatio...
    Medical condition: Treatment of diabetic kidney disease (adults) and chronic kidney disease (children).
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000745-21 Sponsor Protocol Number: P1200_12 Start Date*: 2012-12-10
    Sponsor Name:Schriners Hospitals for Children
    Full Title: An international, multicenter, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta
    Medical condition: Children suffering from severe Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004044-37 Sponsor Protocol Number: GS-US-342-1142 Start Date*: 2017-12-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of SOF/VEL in Healthy Adult Subjects.
    Medical condition: Chronic Hepatitis C virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004966-17 Sponsor Protocol Number: H8D-MC-EMBH Start Date*: 2006-08-28
    Sponsor Name:Eli Lilly and Company
    Full Title: PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
    Medical condition: mild essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003697-26 Sponsor Protocol Number: MK8835-006 Start Date*: 2014-07-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of ...
    Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin and sitagliptin.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) FI (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001777-13 Sponsor Protocol Number: 1H_lac_acc Start Date*: 2014-09-10
    Sponsor Name:Radboud umc
    Full Title: The effect of insulin-induced hypoglycemia on brain lactate accumulation and regional cerebral blood flow in patients with type 1 diabetes mellitus with and without hypoglycemia unawareness and non...
    Medical condition: Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003334-36 Sponsor Protocol Number: D5982C00005 Start Date*: 2022-12-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dos...
    Medical condition: Inadequately Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Not Authorised) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-003481-41 Sponsor Protocol Number: CPH-201-201461 Start Date*: 2020-01-17
    Sponsor Name:Croma-Pharma GmbH
    Full Title: A Double-Blinded Randomized Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
    Medical condition: moderate to severe glabellar frown lines at maximum frown
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005035-33 Sponsor Protocol Number: R2477-FOP-1623 Start Date*: 2017-08-15
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004949-34 Sponsor Protocol Number: 248.595 Start Date*: 2006-04-18
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061536 pref
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 17:06:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA